• Refine Query
  • Source
  • Publication year
  • to
  • Language
  • 317
  • 308
  • 45
  • 19
  • 18
  • 17
  • 11
  • 10
  • 10
  • 5
  • 3
  • 2
  • 2
  • 2
  • 1
  • Tagged with
  • 814
  • 495
  • 473
  • 301
  • 253
  • 166
  • 65
  • 63
  • 59
  • 52
  • 52
  • 50
  • 48
  • 41
  • 40
  • About
  • The Global ETD Search service is a free service for researchers to find electronic theses and dissertations. This service is provided by the Networked Digital Library of Theses and Dissertations.
    Our metadata is collected from universities around the world. If you manage a university/consortium/country archive and want to be added, details can be found on the NDLTD website.
91

Childhood Discoid Lupus erythematosus and Antimalarials

Meurer, Michael 28 February 2014 (has links) (PDF)
Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich.
92

Derivation of an Appropriate Outcome Measure in Lupus

Touma, Zahi 31 August 2012 (has links)
Aim: To develop an outcome measure to identify “responders” for patients who had a clinically important improvement in lupus disease activity with treatment. Methods: The outcome measure derived was based on the commonly used disease activity measure SLEDAI-2K which documents findings over the previous 10 days. Since patients in drug trials are followed at monthly intervals it was necessary to validate SLEDAI-2K 30 days against SLEDAI-2K 10 days. Two prospective studies were accomplished for this purpose. SLEDAI-2K 30 days was used to develop the new responder index, SLEDAI-2K Responder Index-50 (SRI-50). The SRI-50 data retrieval form was developed to standardize the documentation of the descriptors. The construct validity of SRI-50 was prospectively evaluated against an external construct. The reliability of SRI-50 was tested in a multi-centre study. A retrospective analysis over 10 years was used to further validate SRI-50. SRI-50 ability to enhance the SLE Responder Index (SRI) in detecting “responders” was evaluated. The performance of SRI-50 was investigated against SLEDAI-2K and SRI over 12 months. Results: SLEDAI-2K 30 days was validated to describe disease activity over the previous 30 days. The responder index to SLEDAI-2K, SRI-50 was developed including the SRI-50 Definitions and SRI-50 Data Retrieval Forms. The initial validation of SRI-50 confirmed its construct validity to identify ≥ 50 % improvement. SRI-50 is reliable and can be used by both rheumatologists and trainees. The retrospective analysis confirmed that SRI-50 is valid in identifying ≥ 50 % improvement in an efficient time. SRI-50 enhances the performance of SRI and identifies more “responders” than SLEDAI-2K and SRI at 6 and 12 months. Conclusions: SRI-50, is a valid and reliable responder index to identify patients with partial, ≥50% improvement in disease activity in an efficient time. SRI-50 can be used as an independent outcome measure of improvement in patients with SLE.
93

Derivation of an Appropriate Outcome Measure in Lupus

Touma, Zahi 31 August 2012 (has links)
Aim: To develop an outcome measure to identify “responders” for patients who had a clinically important improvement in lupus disease activity with treatment. Methods: The outcome measure derived was based on the commonly used disease activity measure SLEDAI-2K which documents findings over the previous 10 days. Since patients in drug trials are followed at monthly intervals it was necessary to validate SLEDAI-2K 30 days against SLEDAI-2K 10 days. Two prospective studies were accomplished for this purpose. SLEDAI-2K 30 days was used to develop the new responder index, SLEDAI-2K Responder Index-50 (SRI-50). The SRI-50 data retrieval form was developed to standardize the documentation of the descriptors. The construct validity of SRI-50 was prospectively evaluated against an external construct. The reliability of SRI-50 was tested in a multi-centre study. A retrospective analysis over 10 years was used to further validate SRI-50. SRI-50 ability to enhance the SLE Responder Index (SRI) in detecting “responders” was evaluated. The performance of SRI-50 was investigated against SLEDAI-2K and SRI over 12 months. Results: SLEDAI-2K 30 days was validated to describe disease activity over the previous 30 days. The responder index to SLEDAI-2K, SRI-50 was developed including the SRI-50 Definitions and SRI-50 Data Retrieval Forms. The initial validation of SRI-50 confirmed its construct validity to identify ≥ 50 % improvement. SRI-50 is reliable and can be used by both rheumatologists and trainees. The retrospective analysis confirmed that SRI-50 is valid in identifying ≥ 50 % improvement in an efficient time. SRI-50 enhances the performance of SRI and identifies more “responders” than SLEDAI-2K and SRI at 6 and 12 months. Conclusions: SRI-50, is a valid and reliable responder index to identify patients with partial, ≥50% improvement in disease activity in an efficient time. SRI-50 can be used as an independent outcome measure of improvement in patients with SLE.
94

Soluble CD95

Lopik, Thea van. January 2000 (has links)
Proefschrift Universiteit van Amsterdam. / Met lit. opg. - Met samenvatting in het Nederlands.
95

The role of peripheral dendritic cells in systemic lupus erythematosus

Jin, Ou, January 2007 (has links)
Thesis (Ph. D.)--University of Hong Kong, 2008. / Also available in print.
96

The role of peripheral dendritic cells in systemic lupus erythematosus /

Jin, Ou, January 2007 (has links)
Thesis (Ph. D.)--University of Hong Kong, 2008. / Also available online.
97

Beiträge zur Frage der Tuberkulide und des Lupus Erythematodes ....

Ruete, Alfred E., January 1916 (has links)
Habilitationsschrift--Marburg. / "Literatur-Verzeichnis": p. 58.
98

Mannose-binding lectin and systemic lupus erythematosus : molecular studies /

Ip, Wai-kee, Eddie. January 1998 (has links)
Thesis (M. Phil.)--University of Hong Kong, 1999. / Includes bibliographical references (leaves 108-130).
99

Pathogenesis of systemic lupus erythematosus : interactions between anti-DNA antibodies and vascular endothelial cells /

Chan, Tak-mao, Daniel. January 1994 (has links)
Thesis (M.D.)--University of Hong Kong, 1995. / Includes bibliographical references (leaf 172-203).
100

Pathogenesis of systemic lupus erythematosus interactions between anti-DNA antibodies and vascular endothelial cells /

Chan, Tak-mao, Daniel. January 1994 (has links)
Thesis (M.D.)--University of Hong Kong, 1995. / Includes bibliographical references (leaf 172-203). Also available in print.

Page generated in 0.0242 seconds